Novel evaluations of patients with Primary Pneumothorax using xenon enhanced MRI scan and advanced lung function tests.

Oxford Sub-study of Randomised Ambulatory Management of Primary Pneumothorax

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN56742377

Enrollment

Registered

2018-08-15

Start date

2017-02-08

Completion date

Unknown

Last updated

2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Specialty: Respiratory disorders, Primary sub-specialty: Respiratory disorders

Interventions

Ideally within the first 3 months post removal of chest drain, patients will be asked to attend for Xe-129 MRI scan and Lung Function Test: standard and using the Laser Gas Analyser. Xe-129 lung MRI r

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Recruited into RAMPP study through the Oxford or Reading centre (both interventional and observational cohort patients) 2. Participant is willing and able to give informed consent for participation in the study 3. Female participants of child bearing potential must agree to take appropriate steps to avoid pregnancy in the three months following the hyperpolarized xenon lung MRI scan 4. Male or female, aged 16-55

Exclusion criteria

Exclusion criteria: 1. Inability to consent or comply with the trial requirements. 2. Inability to lie flat for procedures. 3. Contraindication to MRI examination (e.g. indwelling pacemaker, non-MRI compatible metallic implant, severe claustrophobia, intra-ocular foreign body). 4. Female participants who are pregnant, lactating or planning pregnancy during the course of the study. 5. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the trial, or the participant’s ability to participate in the study. 6. Epilepsy requiring on-going medical treatment, or a seizure within the past year.

Design outcomes

Primary

Measure	Time frame
Co-primary outcome measures: 1. Comparison of hyperpolarized Xe-129 MRI ventilation and diffusion-weighted maps i.e. percentage ventilation volumes (%VV) and ADC values (cm2/s) with findings from normal control patients (data collected from previous Xe MRI study) and correlation with recurrence rates at 12 months follow-up (in RAMPP study) 2. Ventilation/Volume abnormalities in PSP in comparison with standard lung function and with normal controls (from previous laser gas analyser study)	—

Measure

Time frame

Co-primary outcome measures: 1. Comparison of hyperpolarized Xe-129 MRI ventilation and diffusion-weighted maps i.e. percentage ventilation volumes (%VV) and ADC values (cm2/s) with findings from normal control patients (data collected from previous Xe MRI study) and correlation with recurrence rates at 12 months follow-up (in RAMPP study) 2. Ventilation/Volume abnormalities in PSP in comparison with standard lung function and with normal controls (from previous laser gas analyser study)

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026